Core Viewpoint - Reap Bio (300119) announced on September 12 that as of September 10, 2025, the total number of shareholders is approximately 26,000 [1] Company Summary - Reap Bio has reported a total shareholder count of about 26,000 as of the specified date [1]

Core Viewpoint - The company, Reap Bio (300119), announced its share repurchase and dividend distribution plans, highlighting its commitment to returning value to shareholders through significant cash dividends and stock repurchases [1] Group 1: Share Repurchase - In 2023 and 2024, the company plans to repurchase a total of 10.68 million shares [1] - The total amount allocated for the share repurchase is 190 million RMB [1] Group 2: Dividend Distribution - Since its listing, the company has distributed a total of 1.371 billion RMB in cash dividends [1] - The average dividend payout ratio stands at 44.32% [1] - The company has executed four stock splits, resulting in a 5.27 times expansion of its share capital compared to before its initial public offering [1]

Group 1 - The company, Ruipeng Biotech (300119), announced on September 12 that it will provide information regarding the operation of Ruipeng Pet Hospital through official channels only [1]

证券日报网讯 瑞普生物9月12日发布公告，在公司回答调研者提问时表示，为推动原料药板块提质增 效，公司重点实施三大关键举措：一是深化精益降本，通过对产品生产工艺、全生产流程开展精准诊断 优化，并加强集中采购管理，有效降低单位生产成本；二是加速海外市场拓展，继续扩大出口份额；三 是优化产品结构，提升高毛利产品占比，下半年还将推出盐酸沃尼妙林二水合物、头孢噻呋晶体等新产 品，进一步丰富高附加值产品矩阵，以提高综合盈利水平。 （编辑 袁冠琳） ...

（编辑 袁冠琳） 证券日报网讯 瑞普生物9月12日发布公告，在公司回答调研者提问时表示，公司高度重视股价与创业板 指数的拟合情况。从基本面看，2025年上半年公司营收17.08亿元、归母净利润2.57亿元，同比分别增长 20.53%、57.59%，盈利端保持高速增长，为市值提供核心支撑。公司"经济动物生物制品+宠物医疗"业 务布局扎实，相信长期价值会被市场认可。 ...

Core Viewpoint - The company announced that it expects to launch cat interferon in the market this year, while the development of the cat quadrivalent vaccine is still ongoing [1] Group 1 - The company is actively preparing to advance its research and development efforts for the cat quadrivalent vaccine and aims to enter clinical trials as soon as possible [1]

Core Viewpoint - The company, Reap Bio, announced the launch of several new products in its biopharmaceutical, drug formulation, and pet care segments for the second half of the year, focusing on advanced vaccine technology and innovative treatments for various animal health needs [1] Group 1: Biopharmaceutical Segment - The company plans to introduce new vaccines, including the new dual live vaccine and new inactivated vaccines targeting key poultry diseases, enhancing multi-valent technology and broad-spectrum antigens [1] - The upgrades aim to meet diverse vaccination needs across different farming scenarios, indicating a strategic focus on addressing core disease challenges in poultry farming [1] Group 2: Drug Formulation Segment - The company will launch its independently developed long-acting sustained-release formulation of Cefoperazone crystals and its injectable form [1] - Additionally, it will introduce a new crystal form of Vornidazole hydrochloride with independent intellectual property rights, targeting Mycoplasma infections in poultry for the first time [1] Group 3: Pet Care Segment - The company aims to enhance its product matrix in the pet care sector by launching new products such as cat interferon, krill oil, and probiotics [1] - This initiative is part of a broader strategy to provide a comprehensive range of products from prevention to treatment and nutritional health, showcasing the continued emphasis on product cluster scale effects [1]

Core Viewpoint - The company emphasizes innovation-driven high-quality development in response to profound changes in the animal health industry [1] Group 1: Strategic Initiatives - The company is accelerating the development of third-generation vaccines and new drugs [1] - There is a continuous deepening of strategic cooperation with breeding groups [1] Group 2: Long-term Strategies - The company is advancing internationalization, pet economy, and synthetic biology as part of its medium to long-term strategies [1] - These initiatives are aimed at laying a solid foundation for high-quality development and creating long-term investment value for shareholders [1]

Market Overview - The animal health sector experienced a decline of 0.21% on September 12, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Individual Stock Performance - Shunlian Biological (688098) closed at 11.85, up 2.07% with a trading volume of 85,100 shares and a turnover of 99.05 million yuan [1] - KQ Biological (688526) closed at 18.63, up 0.70% with a trading volume of 19,700 shares and a turnover of 36.27 million yuan [1] - Huisheng Biological (300871) closed at 22.55, up 0.53% with a trading volume of 54,100 shares and a turnover of 122 million yuan [1] - Dayu Biological (871970) led the decline, closing at 10.73, down 3.85% with a trading volume of 76,600 shares and a turnover of 82.31 million yuan [2] Capital Flow Analysis - The animal health sector saw a net outflow of 15.44 million yuan from institutional investors, while retail investors experienced a net outflow of 9.04 million yuan [2] - Speculative funds recorded a net inflow of 24.47 million yuan [2] Detailed Capital Flow for Selected Stocks - Shunlian Biological had a net inflow of 14.94 million yuan from institutional investors, but a net outflow of 21.09 million yuan from retail investors [3] - Huisheng Biological experienced a net outflow of 7.83 million yuan from institutional investors, while retail investors had a net inflow of 9.81 million yuan [3] - KQ Biological saw a net outflow of 1.73 million yuan from institutional investors, with a minor net inflow from retail investors [3]

Competitive Advantages - Reap Bio is one of the largest and most comprehensive veterinary drug companies in China, with significant R&D advantages, including 117 new veterinary drug registration certificates and an annual R&D investment exceeding 100 million RMB [2][3] - The company has a full product line system that provides a closed-loop service from detection to clinical validation, helping to reduce costs and improve efficiency for clients [2][3] - The company has a notable first-mover advantage in the pet medicine sector, with 17 new veterinary drug registration certificates for pets and strategic layouts in innovative drugs and mRNA vaccines [3] Strategic Development - Reap Bio is focusing on high-quality development driven by innovation, accelerating the development of third-generation vaccines and new drugs, and deepening strategic cooperation with breeding groups [3][4] - The company is actively pursuing internationalization and exploring potential sectors such as synthetic biology to create new growth drivers [3][4] Product Launches and Innovations - Key products to be launched in the second half of 2025 include new vaccines and long-acting formulations, aimed at addressing core diseases in poultry farming [7][8] - The company is also expanding its product matrix in the pet sector with new offerings such as cat interferon and probiotics, enhancing its comprehensive product range [7][8] Financial Performance - In the first half of 2025, the company reported revenue of 1.708 billion RMB and a net profit of 257 million RMB, representing year-on-year growth of 20.53% and 57.59% respectively [14] - The company has repurchased 10.68 million shares, with a total repurchase amount of 1.9 billion RMB, maintaining a cash dividend payout ratio of 44.32% [14] Market Position and Future Outlook - The company is committed to maintaining its market position in the pet medical sector and is exploring potential mergers and acquisitions to strengthen its competitive edge [12][13] - Reap Bio is also focusing on enhancing its online sales channels and integrating its products with pet hospitals to increase customer traffic and sales [7][8]